

# Kelly-Anne Phillips, Mbbs

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2621943/kelly-anne-phillips-mbbs-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140  
papers

7,773  
citations

42  
h-index

86  
g-index

148  
ext. papers

9,620  
ext. citations

7.5  
avg, IF

5.25  
L-index

#	Paper	IF	Citations
140	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 2402-2416	27.4	1140
139	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , <b>2017</b> , 551, 92-94	50.4	643
138	Cognitive function in breast cancer patients receiving adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2695-701	2.2	452
137	Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 923-32	59.2	352
136	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1347-61	27.4	286
135	Obesity and outcomes in premenopausal and postmenopausal breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1686-91	4	253
134	The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. <i>Brain and Cognition</i> , <b>2005</b> , 59, 60-70	2.7	236
133	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 680-691	36.3	190
132	The Y deletion gr/gr and susceptibility to testicular germ cell tumor. <i>American Journal of Human Genetics</i> , <b>2005</b> , 77, 1034-43	11	172
131	Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 121, 389-98	4.4	139
130	CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4308-16	2.2	134
129	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , <b>2006</b> , 15, 443-51	5.6	127
128	Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. <i>Breast Cancer Research</i> , <b>2006</b> , 8, R12	8.3	125
127	Key steps for effective breast cancer prevention. <i>Nature Reviews Cancer</i> , <b>2020</b> , 20, 417-436	31.3	120
126	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3091-9	2.2	118
125	Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 19-26	2.2	116
124	Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1053-61	8.7	112

123	Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 190-7	9.7	111
122	Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4679-86	2.2	95
121	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , <b>2016</b> , 48, 374-86	36.3	93
120	Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3653-63	2.2	82
119	Putting the risk of breast cancer in perspective. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 141-4	59.2	80
118	Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1555; author reply 1556	59.2	78
117	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , <b>2020</b> , 52, 572-581	36.3	76
116	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 3926-39	5.6	75
115	10-year performance of four models of breast cancer risk: a validation study. <i>Lancet Oncology</i> , <b>2019</b> , 20, 504-517	21.7	73
114	Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. <i>Human Reproduction</i> , <b>2016</b> , 31, 1126-32	5.7	72
113	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3628-3637	12.9	68
112	Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 359-65	4	68
111	Psychosocial factors and survival of young women with breast cancer: a population-based prospective cohort study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4666-71	2.2	65
110	Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. <i>Breast</i> , <b>2010</b> , 19, 388-95	3.6	62
109	Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. <i>Clinical Genetics</i> , <b>2006</b> , 70, 198-206	4	59
108	Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 699-705	2.2	58
107	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. <i>Lancet Oncology</i> , <b>2005</b> , 6, 581-8	21.7	55
106	Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 126, 221-6	4.4	52

105	Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. <i>Journal of the American Geriatrics Society</i> , <b>2009</b> , 57, 403-11	5.6	50
104	HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. <i>Cancer</i> , <b>2002</b> , 95, 2068-75	6.4	49
103	Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 210-213	9.7	49
102	Prevalence of self-reported arm morbidity following treatment for breast cancer in the Australian Breast Cancer Family Study. <i>Breast</i> , <b>2001</b> , 10, 515-22	3.6	47
101	Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. <i>Familial Cancer</i> , <b>2005</b> , 4, 105-13	3	46
100	Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 531-42	4.4	43
99	Predictors of breast cancer screening behavior in women with a strong family history of the disease. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 124, 509-19	4.4	42
98	Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 621-8	7.5	39
97	Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. <i>Clinical Genetics</i> , <b>2000</b> , 57, 376-83	4	39
96	Identification of novel genetic markers of breast cancer survival. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	38
95	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , <b>2015</b> , 13, 156	11.4	37
94	Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 683-92	7.8	37
93	Contralateral prophylactic mastectomy (CPM): A systematic review of patient reported factors and psychological predictors influencing choice and satisfaction. <i>Breast</i> , <b>2016</b> , 28, 107-20	3.6	37
92	Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 1296-301	8.7	36
91	Screening behavior in women at increased familial risk for breast cancer. <i>Familial Cancer</i> , <b>2006</b> , 5, 359-68		36
90	Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. <i>Human Genetics</i> , <b>2003</b> , 112, 542-51	6.3	36
89	Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3920-5	2.2	35
88	Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. <i>Medical Journal of Australia</i> , <b>2013</b> , 199, 680-3	4	35

87	Morphological predictors of BRCA1 germline mutations in young women with breast cancer. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 903-9	8.7	35
86	The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2010</b> , 28, 492-9	2.8	35
85	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 1653-1666	8.1	34
84	Assessing and managing breast cancer risk: clinicians' current practice and future needs. <i>Breast</i> , <b>2014</b> , 23, 644-50	3.6	33
83	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. <i>Genetics in Medicine</i> , <b>2017</b> , 19, 30-35	8.1	31
82	Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 247-52	5	31
81	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 956-64	8.7	30
80	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 52	8.3	29
79	A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer. <i>Medical Decision Making</i> , <b>2006</b> , 26, 360-72	2.5	28
78	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 1814-1822	7.8	27
77	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120020	3.7	26
76	iPrevent <sup>®</sup> : a tailored, web-based, decision support tool for breast cancer risk assessment and management. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 171-82	4.4	25
75	Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 139, 887-96	4.4	25
74	Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 1792-7	4	25
73	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 58	8.3	24
72	Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 120, 715-23	4.4	23
71	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 8	8.3	22
70	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 93, 417-21	4.9	20

69	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 804-805	2.2	18
68	Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 117, 167-76	4.4	18
67	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 18	8.3	17
66	The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. <i>Human Reproduction</i> , <b>2020</b> , 35, 1864-1874	5.7	16
65	Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory. <i>Patient Education and Counseling</i> , <b>2016</b> , 99, 814-22	3.1	16
64	Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 130, 1057-61	4.4	16
63	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. <i>Familial Cancer</i> , <b>2009</b> , 8, 451-6		16
62	Australian clinicians and chemoprevention for women at high familial risk for breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , <b>2009</b> , 7, 9	2.3	16
61	Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 225-32	2.2	16
60	Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. <i>Clinical Genetics</i> , <b>2003</b> , 64, 111-21	4	16
59	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 386-401	4.9	15
58	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , <b>2016</b> , 27, 679-93	2.8	15
57	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. <i>Cancer Research</i> , <b>2020</b> , 80, 116-125	10.1	15
56	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , <b>2014</b> , 5, 4051	17.4	13
55	Women's preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory. <i>Patient Education and Counseling</i> , <b>2014</b> , 96, 106-12	3.1	13
54	Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. <i>Australian Journal of Primary Health</i> , <b>2016</b> , 22, 255-261	1.4	13
53	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky023	4.6	13
52	Chemotherapy for soft tissue sarcomas. Indications and advances. <i>Acta Orthopaedica</i> , <b>1997</b> , 273, 133-8		11

51	Preventing ovarian failure associated with chemotherapy. <i>Medical Journal of Australia</i> , <b>2018</b> , 209, 412-416		11
50	Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?. <i>Breast</i> , <b>2017</b> , 31, 233-240	3.6	10
49	Clinical management of women at high risk of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2015</b> , 27, 6-13	2.4	10
48	Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer. <i>Familial Cancer</i> , <b>2013</b> , 12, 101-9	3	10
47	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , <b>2020</b> , 44, 442-468	2.6	9
46	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 368-378	4	9
45	Current perspectives on BRCA1- and BRCA2-associated breast cancers. <i>Internal Medicine Journal</i> , <b>2001</b> , 31, 349-56	1.6	9
44	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 225, 51.e1-51.e17	6.4	9
43	Predicting women's intentions for contralateral prophylactic mastectomy: An application of an extended theory of planned behaviour. <i>European Journal of Oncology Nursing</i> , <b>2016</b> , 21, 57-65	2.8	8
42	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). <i>Breast Cancer Research</i> , <b>2019</b> , 21, 128	8.3	8
41	Does stress increase risk of breast cancer? A 15-year prospective study. <i>Psycho-Oncology</i> , <b>2018</b> , 27, 1908-1914	3.9	7
40	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz066	4.6	7
39	Genetic testing in women with breast cancer: implications for treatment. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 991-1002	3.5	7
38	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkz075	4.6	7
37	Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 36-39	8.7	6
36	Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer. <i>American Journal of Epidemiology</i> , <b>2017</b> , 185, 487-500	3.8	5
35	Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. <i>Familial Cancer</i> , <b>2011</b> , 10, 505-14	3	5
34	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. <i>JMIR Formative Research</i> , <b>2018</b> , 2, e24	2.5	5

33	Comparing 5-Year and Lifetime Risks of Breast Cancer Using the Prospective Family Study Cohort. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 785-791	9.7	5
32	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 370-379	7.5	4
31	Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer. <i>Familial Cancer</i> , <b>2014</b> , 13, 153-62	3	4
30	Medication to prevent breast cancer--too much to swallow?. <i>Medical Journal of Australia</i> , <b>2011</b> , 195, 646-9	7	4
29	Socio-economic status and survival from breast cancer for young, Australian, urban women. <i>Australian and New Zealand Journal of Public Health</i> , <b>2010</b> , 34, 200-5	2.3	4
28	Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 1396-8	4	4
27	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , <b>2021</b> , 12, 1078	17.4	4
26	Conservative management of reproductive cancers. Ovarian protection during treatment. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2019</b> , 55, 49-58	4.6	3
25	Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique. <i>SpringerPlus</i> , <b>2014</b> , 3, 264		3
24	An online educational facility for medical oncology trainees: www.vmotg.org. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2566-9	2.2	3
23	Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. <i>Cancer Prevention Research</i> , <b>2021</b> , 14, 131-144	3.2	3
22	Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa110	4.6	3
21	Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. <i>Hereditary Cancer in Clinical Practice</i> , <b>2007</b> , 5, 161-3	2.3	2
20	Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT) <b>2015</b> ,		2
19	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 131-139	4.9	2
18	Survival from breast cancer in women with a BRCA2 mutation by treatment. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1524-1532	8.7	2
17	Bilateral Salpingo-oophorectomy and Breast Cancer Risk for and Mutation Carriers: Assessing the Evidence. <i>Cancer Prevention Research</i> , <b>2021</b> , 14, 983-994	3.2	2
16	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. <i>Journal of the National Cancer Institute</i> , <b>2022</b> ,	9.7	1



15	Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e20660-e20660	2.2	1
14	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 17-17	2.2	1
13	Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e14098-e14098	2.2	1
12	Abortion and breast cancer risk for Australian women. <i>Medical Journal of Australia</i> , <b>2014</b> , 201, 381	4	1
11	Screening and Diagnosis of Ovarian Cancer High Risk <b>2004</b> , 341-354		1
10	Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	1
9	Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1401	13.4	1
8	The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations. <i>Medical Journal of Australia</i> , <b>2021</b> , 215, 460-464	4	0
7	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk.. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkab090	4.6	0
6	Unexpected diagnosis of spinal leptomeningeal metastatic disease on MRI myelography. <i>Journal of Clinical Neuroscience</i> , <b>2019</b> , 66, 259-261	2.2	
5	Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation.. <i>Cancer Treatment and Research Communications</i> , <b>2022</b> , 30, 100504	2	
4	Management of Women at High Familial Risk of Breast and Ovarian Cancer <b>2009</b> , 941-967		
3	Maximizing the Clinical Benefit of Genotyping: Extending the Opportunity of Personalized Management to Family Members Through Cascade Testing.. <i>JCO Precision Oncology</i> , <b>2018</b> , 2, 1-5	3.6	
2	Underutilisation of breast cancer prevention medication in Australia. <i>Breast</i> , <b>2021</b> , 60, 35-37	3.6	
1	Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials?. <i>Cancer Research</i> , <b>2022</b> , 82, P5-19-03-P5-19-03	10.1	